Genomic Health announced this week it is on track for a 2013 launch of its Oncotype Dx test to help doctors distinguish between aggressive and indolent prostate cancer.

According to the company, a large clinical validation trial performed in collaboration with the University of California, San Francisco, has met its primary endpoint demonstrating that the Oncotype DX prostate cancer risk score can discern which early-stage patients are at risk of disease progression. The test analyzes tumor tissue prostate needle biopsies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.